ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $29,789.76 in Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 2,976 shares of ORIC Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $10.01, for a total value of $29,789.76. Following the completion of the transaction, the chief financial officer now directly owns 102,117 shares in the company, valued at $1,022,191.17. This represents a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Dominic Piscitelli also recently made the following trade(s):

• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $3,000.00.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $10.01, for a total value of $26,026.00.

ORIC Pharmaceuticals Stock Down 0.4%

ORIC stock opened at $9.63 on Friday. ORIC Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67. The stock’s 50 day moving average is $6.15 and its two-hundred day moving average is $7.71. The company has a market capitalization of $684.58 million, a PE ratio of -5.29 and a beta of 1.49.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09. As a group, sell-side analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Alkeon Capital Management LLC increased its holdings in shares of ORIC Pharmaceuticals by 2.6% in the 1st quarter. Alkeon Capital Management LLC now owns 4,004,096 shares of the company’s stock valued at $22,343,000 after acquiring an additional 100,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of ORIC Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 3,215,887 shares of the company’s stock valued at $17,945,000 after acquiring an additional 12,098 shares during the last quarter. Vivo Capital LLC increased its holdings in shares of ORIC Pharmaceuticals by 62.8% in the 1st quarter. Vivo Capital LLC now owns 2,080,450 shares of the company’s stock valued at $11,609,000 after acquiring an additional 802,632 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of ORIC Pharmaceuticals in the 4th quarter valued at approximately $13,982,000. Finally, NEA Management Company LLC increased its holdings in shares of ORIC Pharmaceuticals by 4.4% in the 4th quarter. NEA Management Company LLC now owns 1,566,081 shares of the company’s stock valued at $12,638,000 after acquiring an additional 66,081 shares during the last quarter. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. Oppenheimer reduced their price target on ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Thursday, May 29th. Finally, JPMorgan Chase & Co. boosted their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ORIC Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.17.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.